Maximum Reduction. The maximum aggregate reduction with respect to the royalty rate for a Product in any calendar quarter during the applicable Royalty Term in any country pursuant to Sections 3.1.5 (Royalty Reduction), 3.1.6 (Biosimilar Competition) and 3.1.7 (Third-Party Intellectual Property) shall be [***].
Appears in 3 contracts
Samples: Exclusive License Agreement (Akero Therapeutics, Inc.), Exclusive License Agreement (Akero Therapeutics, Inc.), Exclusive License Agreement (Akero Therapeutics, Inc.)
Maximum Reduction. The maximum aggregate reduction with respect to the royalty rate for a any Product in any calendar quarter during the applicable Royalty Term in any country pursuant to Sections 3.1.5 8.2.5 (Royalty Reduction), 3.1.6 (Biosimilar Competition) and 3.1.7 8.2.6 (Third-Party Intellectual Property) shall be […***…] percent ([…***…]%).
Appears in 2 contracts
Samples: Research Collaboration and License Agreement (Kite Pharma, Inc.), Research Collaboration and License Agreement (Kite Pharma, Inc.)
